Recent studies have shown that PAX5 is silenced by promoter hypermethylation in some types of human cancers including hepatocellular carcinoma 17, gastric cancer 10, breast cancer 18, lung cancer and lymphoid neoplasm 14, 19. Here, PAX5 is linked to lung cancer.